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Abstract 
In veterinary medicine, assay performance is often affected by the lack of species-specific 
diagnostic tools. Reliable biomarkers might be identified by investigating biological fluids of 
the species of interest, but protein sequence databases are often incomplete and human-
specific devices for reducing sample complexity might fail when applied to animal plasma. 
Here, seven commercial methods based on different capturing agents (anti-human antibodies, 
affinity ligands, mixture of antibodies and ligands, and combinatorial peptide ligand libraries) 
were applied to cat plasma and evaluated in terms of yield, identified proteins/ peptides, and 
relative abundance by high resolution shotgun proteomics and label-free quantitation. As a 
result, anti-human antibody-based methods were unsatisfactory. Most failed in reducing 
albumin and immunoglobulins, and some led to a substantial removal of other highly 
abundant proteins, probably because of nonspecific interactions. A protein A/dye ligand-
based method was efficient in reducing immunoglobulins, fibrinogen and apolipoprotein A1 
and A2, but not albumin, and protein identifications did not increase. Only peptide ligand 
libraries flattened the dynamic range, and increased protein identification (59.0%). Albumin 
and immunoglobulins were successfully depleted (60.7% and 35.9%, respectively). Although 
further studies will be required for reinforcing our observations, this work can provide a 
useful guide for cat plasma pretreatment in biomarker discovery studies. 
 
 
Farm animal and pet welfare is the main goal of veterinary medicine for both economic and 
affection reasons. Nowadays, the performance of animal diagnostic serology is often sub-
optimal, mostly due to the low availability of commercial species-specific immunoassays [1]. 
Even though clinical care may capitalize from what has already been discovered by human 
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system biology, dedicated biomarker discovery and validation efforts would be needed for 
improving veterinary diagnostics [2]. Nevertheless, compared to humans, biomarker 
discovery studies directly performed on animal specimens lag considerably behind [3-5]. This 
might be partly due to specific difficulties in treating samples and to the limited availability 
of annotated protein sequence databases [6]. One of the main problems in proteomic analysis 
of biological specimens such as plasma, serum, and urine, is the presence of a huge dynamic 
molecular range of protein concentration [7-9]. The availability of commercial products 
aimed at depleting highly abundant protein and enriching the low abundant ones generally 
enables a more efficient and less challenging biomarker discovery process. However, most 
commercial solutions based on immunoaffinity criteria have been developed for human 
specimens, and only a limited number of products are specific for, or compatible with some 
animal species [10-13]. Other products are composed by a mixture of affinity ligands (protein 
G or protein A, dye ligands, peptide libraries), theoretically allowing their use on a wider 
range of organisms [14-16]. To our knowledge, no antibody-based depletion kit has been 
declared by the manufacturers as suitable for feline samples, and only a limited number of 
papers report proteomic studies on cat biofluids [17], none of them applying procedures for 
depletion/enrichment of highly abundant proteins. Recently, a comparative evaluation of 
seven commercial products was performed by our group on a human serum sample by means 
of a shotgun proteomics approach [18, 19]. Here, we aimed at evaluating the same methods 
on a cat plasma sample to gather information on their depletion performances and to provide 
a selection guide for plasma biomarker discovery studies in this species.  
Different capturing criteria were included: i) immunoaffinity with antibodies directed against 
specific (human) proteins, ii) protein G and antibodies directed against human serum albumin 
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(HSA), iii) protein A and cibacron blue dye-ligand, and iv) affinity for a combinatorial 
peptide ligand library. All products were applied to a pool of plasma samples and the 
enriched proteins were evaluated by SDS-PAGE, high resolution shotgun MS analysis and 
label-free quantitation. 
Plasma samples from four cats were homogeneously pooled and stored at -80°C until use. 
Pool protein concentration was 63 mg/mL based on the BCA assay (Thermo Fisher 
Scientific, CA). Depletions and enrichments were performed according to the product 
manuals with the sample volumes recommended by the manufacturers [18]. Products were 
based on four different capturing agents: antibodies (Qproteome Albumin/IgG Depletion kit, 
“Qproteome”, Qiagen, Sweden; ProteoPrep Immunoaffinity Albumin and IgG Depletion Kit, 
“ProteoPrep”, Sigma-Aldrich, MO; Top 2 Abundant Protein Depletion Spin Columns “Top 
2”, and Top 12 Abundant Protein Depletion Spin Columns “Top 12”, Thermo Fisher 
Scientific), specific ligands (Albumin/IgG Removal, “CibB-A”, Thermo Fisher Scientific), 
mixture of antibodies and ligands (Albumin and IgG Depletion SpinTrap, “SpinTrap”, GE 
Healthcare, Sweden), and combinatorial peptide ligand libraries (ProteoMiner beads, 
“ProteoMiner”, Bio-Rad, CA), respectively. Table S1 summarizes the selected products and 
their relative features. Two technical replicates were performed for each procedure. A non-
reducing Laemmli buffer was added to 10 µg of each depleted/enriched fraction and SDS-
PAGE was carried out on any kD precast polyacrylamide gels using the Mini-Protean system 
(Bio-Rad). Filter aided sample preparation (FASP) was performed on all protein samples to 
obtain tryptic peptide mixtures; LC-MS/MS analysis was carried out on a Q Exactive mass 
spectrometer interfaced with an UltiMate 3000 RSLCnanoLC system (Thermo Fisher 
Scientific), by performing a linear gradient of 245 min from 5% to 37.5% of eluent B (0.1% 
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formic acid in 80% acetonitrile) in eluent A (0.1% formic acid) at a flow rate of 250 nL/min. 
MS data were acquired using a data-dependent top12 method, as previously described [18, 
21]. Proteome Discoverer (version 1.4; Thermo Fisher Scientific) was used for protein 
identification with Sequest-HT as search engine. Raw files were processed with the following 
parameters: database Felis silvestris catus, downloaded from UniProtKB_TrEMBL (release 
2017 08); enzyme trypsin, with two missed cleavages allowed; precursor mass tolerance 10 
ppm; MS/MS tolerance 0.02 Da; charge states +2, +3, and +4; cysteine 
carbamidomethylation as static modification and methionine oxidation as dynamic 
modification. The percolator algorithm was used for protein significance and for peptide 
validation (FDR<0.01%). Uncharacterized proteins were identified by Basic Local Alignment 
Search Tool (BLAST) homology search. 
Relative protein abundance was assessed by label-free quantitation based on the spectral 
counting (SpC) approach, calculating the normalized spectral abundance factor (NSAF) 
according to Old et al. [20]. All statistical analyses were performed using t-test (p-value 
≤0.05). 
According to the manufacturers suggestions, 10 μL of plasma were processed by Top 2, Top 
12 and CibB-A columns, approximately corresponding to 0.63 mg of proteins; 25 μL of 
sample were incubated with SpinTrap, Qproteome and ProteoPrep columns, equivalent to 
1.58 mg of proteins, and a 40 μL aliquot, accounting for 2.52 mg of proteins, was incubated 
with the appropriate volume of ProteoMiner beads, respecting the volume/volume ratio 
suggested by the manufacturer for serum/plasma samples. To evaluate protein yields for each 
product, the concentrations of depleted/enriched fraction were estimated. Unexpectedly, total 
recovery was very high in most of the applied protocols; more in detail, the protein content of 
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recovered fractions spanned from a minimum of 31% for Top 12, to 33% for CibB-A, 35% 
for ProteoPrep, 39% for Top 2, up to a maximum of 48% for SpinTrap and Qproteome, when 
compared to the untreated plasma sample. Only ProteoMiner led to a very low yield of 1.8%, 
suggesting a depletion of a large amount of proteins. These yields were very different from 
the analogues calculated on human serum [18], revealing that both immuno- and chemical-
affinity based products, except for the combinatorial peptide ligand library, have weaker 
interactions with cat plasma proteins.  
To visualize the overall effect of each method, 10 µg aliquots of untreated plasma, of the 
depleted/enriched fractions and of the residual proteins were analyzed by SDS-PAGE. As 
shown in Figure 1, as a result of all procedures but ProteoMiner, the protein profile (red) 
remained very similar to the untreated sample (purple). However, a partial removal of highly 
abundant proteins did occur, as demonstrated by the residual protein fractions collected 
during each procedure (Figure 1, blue), which revealed a depletion of feline serum albumin 
(FSA, gel band at about 50 kDa) and immunoglobulins (Igs, gel bands from the top of the gel 
to about 100 kDa), even though in different amounts. After tryptic digestion, untreated 
plasma and depleted/enriched fractions were analyzed by a long-gradient LC-MS/MS to 
assess protein numbers and identities, and the relative abundance was estimated by label-free 
quantitation. Table 1 and Supplementary Table S2 summarize MS results. The highest 
number of proteins and peptides were identified after ProteoMiner enrichment, showing an 
increase of 59.0% and 24.9% when compared to untreated plasma, respectively. The other 
procedures led to a number of identified proteins quite similar to the undepleted plasma. Only 
CibB-A reduced the number of identified proteins and peptides, probably due to nonspecific 
interactions with many plasma proteins. 
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Further, to assess the effect of treatments on the most abundant proteins, their variation in 
comparison to the untreated sample was calculated. Considering that the sequence identity 
between HSA and FSA is 82.4%, it would be reasonable to expect an efficient removal of this 
protein with an anti-HSA antibody, as reported by others for dog serum albumin (80.1% 
identity with HSA) [13]. Surprisingly, FSA removal was efficient only with the ProteoMiner 
approach, with a depletion of 60.7%; FSA content was slightly reduced by Top 2, whereas its 
amount was even increased by all the other products. CibB-A, despite exploiting a dye ligand 
bait supposed not to be species-specific, produced a 2.2-fold increase in the relative FSA 
content (Figure 2A). Regarding Igs, all the identifications referable to Igs were considered 
and the overall variation was calculated (Figure 2B). The best result was obtained by CibB-A, 
leading to a 59.7% of total Igs decrease, suggesting that protein A has a higher affinity to cat 
Igs than protein G and anti-Igs antibodies. In general, all procedures allowed only a modest 
removal of Igs. Interestingly, results were similar to those seen with human serum [18] on 
other highly abundant proteins; more in detail, upon ProteoMiner treatment, serotransferrin, 
α2-macroglobulin, α1-antitrypsin, haptoglobin, and α1-acid glycoprotein (Accession: 
M3WBQ5, M3WMA9, M3WCX1, M3W4S3, and Q6KCA0, respectively) were decreased, 
whereas fibrinogen α-chain and fibrinogen β-chain (Accession: M3W022, and M3WII3) were 
increased; likewise, CibB-A led to a considerable reduction of fibrinogen. In addition, CibB-
A induced a substantial decrease of apolipoprotein A1 and A2 (Accession: M3WPG6, and 
M3WN87) and an increase of serotransferrin, α2-macroglobulin, α1-antitrypsin, haptoglobin, 
and α1-acid glycoprotein contents. The other products, apart from few variations consisting 
in a slight decrease of fibrinogen α-chain and fibrinogen β-chain by Top 12, an increase of 
α1-antitrypsin by both Top 2 and Top 12, and of α1-acid glycoprotein by SpinTrap and 
QProteome, did not effect the most abundant proteins. Further, the effect on low abundant 
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proteins was evaluated; a total of 302 proteins were identified only by the ProteoMiner 
approach (Supplementary Table S3). Among them, many human homologous proteins have 
been reported to be present in ng/mL (tenascin X, [22], thrombomodulin [23] and others) to 
pg/mL (inhibin B, [24]) concentrations in serum samples from normal subjects. 
In conclusion, our data demonstrate that anti-human antibody-based methods are not suitable 
for cat plasma samples. On the other hand, CibB-A was very efficient in reducing Igs, 
fibrinogen and apolipoprotein A1 and A2; noteworthy, ProteoMiner allowed flattening of the 
sample dynamic range and a significant increase in the number of identified proteins. It is 
likely that the binding affinities of anti-human antibodies, protein G and cibacron blue dye-
ligand are not adequate for cat proteins removal, even in case of high sequence identity with 
the homologous human protein. Protein capture with ProteoMiner beads, on the contrary, 
occurs efficiently due to the presence of several millions of different ligands that capture 
proteins independently from the host species or protein antigenicity. Further, the analysis of a 
randomly “captured fraction” by sequence affinity-based methods instead of a residual 
“unbound fraction” as in the case of antibody capture is preferable in our opinion. In fact, in 
the latter case residual abundant proteins may persist in the fraction either if all the capture 
sites provided by the system become saturated or if their affinity is not optimal. Although 
further studies carried out on a higher number of samples will be required to reinforce our 
observations, this work provides a useful guide for selecting depletion procedures in 
biomarker discovery studies on cat plasma. 
 
This work was supported by Regione Autonoma della Sardegna, with the grants “Diagnostici 
per ANimali Da REddito e da Affezione”, D.AN.D.RE.A., and “art. 9 LR 20/2015”. 
www.proteomics-journal.com Page 9 Proteomics 
 
This article is protected by copyright. All rights reserved. 
9 
The authors declare no conflict of interest.  
The authors thank Drs Tiziana Cubeddu and Giovanna Casalloni for providing plasma 
samples. 
References 
[1] T. Warnken, K Huber, K. Feige, BMC Vet. Res. 2016, 12, 196. 
[2] R.E. Moore, J Kirwan, M.K. Doherty, P.D. Whitfield, Biomark. Insights 2007, 10 185. 
[3] L. Galeandro, N.S. Sieber-Ruckstuhl, B. Riond, S. Hartnack, R. Hofmann-Lehmann, C.E. 
Reusch, F.S. Boretti, J. Vet. Intern. Med. 2014, 28, 1433. 
[4] R. Tanoue, I. Kume, Y. Yamamoto, K. Takaguchi, K. Nomiyama, S. Tanabe, T. Kunisue, 
J. Chromatogr. A 2018, 2, 30.  
[5] A. Tanca, D Pagnozzi, G.P. Burrai, M. Polinas, S Uzzau, E Antuofermo, M.F. Addis, J. 
Proteomics 2012, 21, 561. 
[6] F. Di Girolamo, A. D’Amato, I. Lante, F. Signore, M. Muraca, L. Putignani, Int. J. Mol. 
Sci. 2014, 15, 15396.  
[7] G. Biosa, M.F. Addis, A. Tanca, S. Pisanu, T. Roggio, S. Uzzau, D. Pagnozzi, J. 
Proteomics 2011, 75, 93.  
[8] A.H. Zhang, H. Sun, G.L. Yan, Y. Han, X.J. Wang, Appl. Biochem. Biotechnol. 2013, 
170, 774.  
[9] S. Filip, K. Vougas, J. Zoidakis, A. Latosinska, W. Mullen, G. Spasovski, H. Mischak, A. 
Vlahou, J. Jankowski, PLoS One 2015, 10, e0133773.  
[10] R. Günther, E. Krause, M. Schümann, J. Ausseil, J.M. Heard, I.E. Blasig, R.F. Haseloff, 
Fluids Barriers CNS 2014, 23, 14.  
www.proteomics-journal.com Page 10 Proteomics 
 
This article is protected by copyright. All rights reserved. 
10 
[11] K. de Morais-Zani, K.F. Grego, A.S. Tanaka, A.M. Tanaka-Azevedo, J. Biomol. Tech. 
2011, 22, 67. 
[12] D.R. Haudenschild, A. Eldridge, P.J. Lein, B.A. Chromy, Biochem. Biophys. Res. 
Commun. 2014, 455, 84. 
[13] M. Sundberg, J. Bergquist, M. Ramström, Biochem. Biophys. Rep. 2015, 3, 68. 
[14] K. Björhall, T. Miliotis, P. Davidsson, Proteomics 2005, 5, 307. 
[15] K. Leecharoenkiat, W. Sornjai, K. Khungwanmaythawee, A. Paemanee, C. Chaichana, 
S. Roytrakul, S. Fucharoen, S. Svasti, D.R. Smith, Dis. Markers 2014, 2014, 340214.  
[16] A. D'Amato, A. Bachi, E. Fasoli, E. Boschetti, G. Peltre, H. Sénéchal, P.G. Righetti, J. 
Proteome Res. 2009, 8, 3925.  
[17] M.D. Meachem, E.R. Snead, B.A. Kidney, M.L. Jackson, R. Dickinson, V. Larson, E. 
Simko, Can. J. Vet. Res. 2015, 79, 184. 
[18] S. Pisanu, G. Biosa, L. Carcangiu, S. Uzzau, D. Pagnozzi, Talanta, 2018, 185, 213.  
[19] S. Pisanu, G. Biosa, L. Carcangiu, S. Uzzau, D. Pagnozzi, Data Brief 2018, 19, 1765. 
[20] W.M. Old, K. Meyer-Arendt, L. Aveline-Wolf, K.G. Pierce, A. Mendoza, J.R. Sevinsky, 
K.A. Resing, N.G. Ahn, Mol. Cell. Proteomics 2005, 4, 1487. 
[21] D. Pagnozzi, F. Tamarozzi, A.M. Roggio, V. Tedde, M.F. Addis, S. Pisanu, G. Masu, C. 
Santucciu, A. Vola, A. Casulli, G. Masala, E. Brunetti, S. Uzzau, Clin. Infect. Dis. 2018, 66, 
1342. 
[22] K. Yamada, A. Watanabe, H. Takeshita, K. Matsumoto, Clin. Chim. Acta 2016, 459, 94. 
www.proteomics-journal.com Page 11 Proteomics 
 
This article is protected by copyright. All rights reserved. 
11 
[23] F. Califano, T. Giovanniello, P. Pantone, E. Campana, C. Parlapiano, F. Alegiani, G.M. 
Vincentelli, P. Turchetti, Eur. Rev. Med. Pharmacol. Sci. 2000, 4, 59. 
[24] T.W. Kelsey, A. Miles, R.T. Mitchell, R.A. Anderson, W.H. Wallace, PLoS One 2016, 
11, e0153843. 
 
 
Figure legends 
Figure 1. SDS-PAGE of plasma fractions with and without treatments. Protein profiles of 
untreated plasma (purple), depleted/enriched fractions (red) and residual proteins (blue) after 
Top 2, Top 12, SpinTrap, Qproteome, ProteoPrep, CibB-A, ProteoMiner. U: unbound protein 
fractions. E: proteins eluted from the resins. M: Precision Plus molecular weight markers 
(Bio-Rad). 
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Figure 2 Abundance (NSAF) variations of serum albumin (panel A) and total 
immunoglobulins (panel B) after plasma treatment. Plotted values represent the average 
NSAF±SD. Asterisks indicate statistically significant differences between untreated and 
depleted/enriched plasma according to t-test, with *p value≤ 0.05 and ** p value≤ 0.01. 
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Table 1. Numbers of identified proteins, peptides, PSMs and Search Inputs in untreated and 
depleted/enriched plasma. 
 
  Proteins CV (%) Peptides CV (%) PSMs CV (%) Search Inputs CV (%) 
Plasma 390 ± 8 1.99 4245 ± 63 1.48 13112 ± 86 0.65 80323 ± 86 0.11 
CibB-A  264 ± 0** 0.00 2214 ± 30** 1.34 10455 ± 71** 0.68 70498 ± 1242** 1.76 
ProteoPrep  353 ± 13 3.61 3932 ± 52* 1.33 12608 ± 66* 0.53 81329 ± 1114 1.37 
SpinTrap  385 ± 16 4.04 4047 ± 65 1.61 13377 ± 213 1.60 78574 ± 1314 1.67 
Top 12  395 ± 7 1.79 4303 ± 24 0.56 13690 ± 74* 0.54 79571 ± 1225 1.54 
Qproteome  396 ± 6 1.61 3872 ± 69* 1.77 13488 ± 601 4.46 77057 ± 2502 3.25 
Top 2  398 ± 7 1.78 4346 ± 13 0.29 13602 ± 71* 0.52 78296 ± 44** 0.06 
ProteoMiner  620 ± 2** 0.34 5303 ± 42** 0.80 15408 ± 65** 0.42 77151 ± 619* 0.80 
Numbers represent the average from technical replicates ± SD. 
CV: coefficient of variation. Significant differences between untreated and depleted/enriched plasma, according to t-test, are 
indicated as * (p value≤0.05), or ** (p value≤0.01). 
 
